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A B S T R A C T
The von Hippel-Lindau (VHL) and cereblon (CRBN) proteins are substrate recognition subunits of two ubiqui-
tously expressed and biologically important Cullin RING E3 ubiquitin ligase complexes. VHL and CRBN are also
the two most popular E3 ligases being recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to
induce ubiquitination and subsequent proteasomal degradation of a target protein. Using homo-PROTACs, VHL
and CRBN have been independently dimerized to induce their own degradation. Here we report the design,
synthesis and cellular activity of VHL-CRBN hetero-dimerizing PROTACs featuring diverse conjugation patterns.
We found that the most active compound 14a induced potent, rapid and profound preferential degradation of
CRBN over VHL in cancer cell lines. At lower concentrations, weaker degradation of VHL was instead observed.
This work demonstrates proof of concept of designing PROTACs to hijack different E3 ligases against each other,
and highlights a powerful and generalizable proximity-induced strategy to achieve E3 ligase knockdown.
1. Introduction
Targeting proteins for degradation by hijacking the ubiquitin-pro-
teasome system with small molecules is a powerful modality of inter-
vention into biology, and an emerging therapeutic strategy.1–4 A pri-
mary approach to targeted protein degradation involves the design of
PROTACs (PROteolysis-Targeting Chimeras). PROTACs are bifunctional
compounds that form a ternary complex with a target protein of interest
and an E3 ubiquitin ligase, such that the target protein is ubiquitinated
by the hijacked E3 ligase and subsequently degraded by the protea-
some.5,6 PROTACs are defined by a catalytic, sub-stoichiometric mode
of action that can allow for rapid, profound and selective target de-
pletion inside cells, and an extended duration of action, also in vivo.7–10
Because their mode of action differs from that of conventional in-
hibitors, the concentrations at which PROTACs exert degradation ac-
tivity are often much lower than expected based on their dissociation
constants with the target protein.11–14 Furthermore, PROTAC’s se-
lectivity can be greater than the binding selectivity of the ligands alone,
allowing to discriminate between highly similar proteins or isoforms in
ways that are not possible with occupancy-based inhibitors.8,11,12,15–17
Within the past four years, potent and selective PROTACs have been
designed to hijack either the von Hippel-Lindau (VHL) or cereblon
(CRBN) E3 ligase against a target protein of interest.18,19 Targets that
have been shown to be degraded by PROTACs include members of
bromodomain-containing proteins such as the BET proteins (Brd2, Brd3
and Brd4),7–9,14,15,17,20,21 amongst other epigenetic protein classes;22–26
protein kinases;10,12,27–31 as well as non-bromodomain and non-kinase
target proteins.32–35 Recent progress in understanding principles of
PROTAC mode of action, and demonstration of applicability across
different target classes, suggest that PROTACs have the potential to
target new protein families, including proteins that are difficult to block
using current approaches. Clinical validation of small molecules indu-
cing protein degradation is provided by recent discoveries on the mo-
lecular mechanism of thalidomide and related clinical anticancer im-
munomodulatory drugs (IMiDs) such as lenalidomide and
pomalidomide, which induce the proteasomal-dependent degradation
of cancer-driving proteins.36,37 More recently, a PROTAC compound
(ARV-110) that targets the androgen receptor for degradation has been
announced as a clinical candidate.38
E3 ubiquitin ligases are key players in the ubiquitin-proteasome
pathway because they catalyse ubiquitination of substrate pro-
teins.39–41 As important regulators of cellular ubiquitination, E3 ligases
are emerging as attractive drug targets, particularly in cancer.42–44
However, E3 ligases have proven difficult to target using small mole-
cule inhibitors. So far only few high-quality inhibitors have been de-
veloped, mainly against the ligases MDM2,45 VHL,46 and IAPs.47 E3
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ligases lack deep binding sites to accommodate endogenous small-mo-
lecule cofactors or substrates, as is the case for ATP in protein kinases.48
Targeting E3 ligases therefore requires disruption (or modulation) of
protein-protein interactions.49 E3 ligase inhibitors face particular
challenges: first, the difficulty to compete with high-affinity en-
dogenous substrates, which increase in level as a result of E3
blockade;50 and second, the observation that small molecules that bind
to E3 ligases may modulate the surface of the targeted E3 in such a way
that new substrate proteins are recruited for degradation, as shown for
the E3 ligases CRBN,37,51,52 and DCAF15.53,54
We hypothesized that the E3 ligases themselves might be hijacked
against one another using a PROTAC approach, thus inducing E3 ligase
degradation as opposed to E3 blockade. In 2017, we disclosed the first
report of a small molecule dimerizer of an E3 ligase as a means to in-
duce its own degradation, an approach that we called “homo-
PROTAC”.11 We designed bifunctional molecules made up of the same
ligand for the ubiquitously expressed VHL protein, connected via a
linker, that would induce VHL dimerization as the key step to trigger
VHL ubiquitination and subsequent degradation. The best degrader, the
symmetric homo-PROTAC CM11 (Figure 1), dimerized VHL in vitro
with high avidity (cooperativity) of∼20-fold, leading to potent, com-
plete and prolonged degradation of VHL in different cell lines. With
CM11, we confirmed the hypothesized mechanism and qualified a
novel chemical probe degrader for VHL.11 Subsequently, the same idea
was applied by Krönke, Gütschow and co-workers, who reported homo-
PROTACs for the CRBN ligase, and showed compound 15a (CC15a in
Figure 1) to be the most active compound.55 As an extension of our
homo-PROTAC approach, we envisaged that two different E3 ligases
could be brought together using hetero-bifunctional PROTACs made of
a ligand handle for one ligase and another handle for a different li-
gase.56 We hypothesized that with such compounds the two E3 ligases
might be hijacked against one another, leading to two potential sce-
narios: 1) both ligases being degraded in cell; 2) one of the two being
preferentially degraded – resulting in one ligase ‘winning’ over the
other one. In the present study, we describe the design, synthesis and
cellular activity of VHL-CRBN heterodimerizing PROTACs, and inter-
rogate the outcome of hijacking these two E3 ligases against each other.
2. Results and discussion
2.1. Design of a library of CRBN-VHL PROTACs
In order to better explore potentially different relative orientations
between the two E3 ligases, we began by designing three series of
heterodimerizers characterized by different attachment points on the
VHL ligase handle (Figure 2): 1) out of the terminal acetyl group of VHL
ligand VH032.50,57 Amidation of a terminal tert-Leu of the VHL ligand
(compound 1, Figure 3) is a widely-explored conjugation strategy for
Figure 1. Previously published homo-PROTACs CM11 and CC15a, which in-
duce self-degradation of the E3 ligases VHL and CRBN, respectively. CM11 and
CC15a are symmetric homodimers of VHL ligand and CRBN ligand pomalido-
mide, respectively.
Figure 2. Design of VHL-CRBN conjugates explored in this work.
Figure 3. Chemical structure of VHL ligands 1 and 2, and CRBN ligand 3.
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PROTACs, including our homo-PROTAC CM11;11 2) via a phenolic
substituent out of VH101, a more potent VHL ligand in which the
cyano-cyclopropyl group of chemical probe VH298 is replaced with a
fluoro-cyclopropyl group, as shown in our published SAR of VHL li-
gands.46 Successful conjugation of this optimized VHL ligand (com-
pound 2, Figure 3) was recently reported by our laboratory in Brd9
degrader VZ185;23 3) via a thioether linkage out of the tert-butyl group
of the VHL ligand, in which the tert-Leu group is replaced with a pe-
nicillamine group, as we previously incorporated in Brd4-selective de-
grader AT1.15 Unlike AT1, in which the VHL ligand handle bears a
terminal acetyl group, here we decided to keep the terminal fluoro-
cyclopropyl group as in VH101. As CRBN handle, we chose pomalido-
mide because of its greater cellular stability compared to other IMiDs.58
To derivatize pomalidomide we appended an ethylenediamine spacer
out of the phthalimide ring (compound 3, Figure 3), to provide a syn-
thetically convenient attachment point for amide conjugation of a
linker.23,29
The linker plays a crucial role in PROTAC design and activity. Small
changes in both length and physicochemical nature e.g. alkylic versus
polyethylene glycol (PEG) as well as mixtures thereof, are known to
impact degradation activity and selectivity in often unpredictable
ways.21,22,31 We therefore decided to explore different linkers, focusing
on varying lengths and ratio between carbon and oxygen atoms, as we
and others have found that these modifications can have a profound
impact on PROTAC structure-activity relationships.21–23,31 As a result,
the designed compounds explore diversity in the derivatization point,
linker length and chemical properties.
2.2. First series of PROTACs.
The first series of VHL-CRBN PROTACs (Figure 2) comprises com-
pounds 7a,b and 14a-e. Compounds 6a and 6b, bearing respectively a 2
and 4 PEG unit linkers, were synthesized as previously reported.11
Briefly, triethylene or pentaethylene glycol were first converted to
monobenzyl ethers and then reacted with tert-butyl bromoacetate under
biphasic conditions to yield linkers 4a-b in good yields (SI Scheme 1).
After deprotection of the benzyl group by catalytic hydrogenation, the
primary alcohol was oxidised to carboxylic acid and subsequently
coupled with VHL ligand 1, as described,11 to afford compounds 6a-b
(SI Scheme1). Deprotection of the tert-butyl group in acidic condition
followed by coupling with CRBN ligand 3 afforded the final PROTACs
7a-b in 95% and 84% yield, respectively (Scheme 1).
For the synthesis of PROTACs 14a-e, symmetric linkers 12a-e
bearing two terminal carboxylate groups were designed with different
length and composition. Compounds 12a-e were prepared starting from
the corresponding diols 10a-e. Diol 10b-e were commercially available,
instead 10a was synthesized in house by adapting a previously reported
method.31 Briefly, 10a was obtained after a nucleophilic substitution
reaction between the tosyl derivative of a monobenzyl protected 1,5
pentadiol and ethylene glycol in a 2:1 ratio, followed by deprotection of
the benzyl group by catalytic hydrogenation (SI Scheme 2). Nucleo-
philic substitution in phase transfer catalysis of diols 10a-e followed by
deprotection in acidic conditions, based on our previously reported
synthetic route,11 delivered compounds 12a-e (SI Scheme 3).
Subsequently, mono N-hydroxysuccinamide ester derivatives of 12a-e,
obtained via reaction with N-hydroxysuccinimide (NHS) and N,N'-di-
cyclohexylcarbodiimide (DCC), were reacted with CRBN ligand 3 in a
2:1 ratio to afford 13a-e (Scheme 2). The NHS activation of the linkers
was required in order to better control the reaction and to reduce the
formation of 2:1 conjugates between 3 and linkers. After removal of
dicyclohexylurea (DCU) side product by filtration, the 1:1 conjugates
13a-e were subsequently coupled with 1 to obtain the final PROTACs
14a-e in 42–62% yields (Scheme 2).
2.3. Second series of PROTACs.
Linkers for the second PROTAC series (Figure 2) were designed to
contain a carboxylic group protected as tert-butyl ester on one side and
a leaving group on the other side, which could be coupled with the
phenol group on VHL ligand 2. Linkers 15a-b were synthesized as
previously reported,31 and their alkyl iodide derivatives 16a-b were
prepared by reaction of the alcohol group with Ph3P·I2 reagent prepared
in situ (Scheme 3). Ligand 2 was reacted with compounds 16a-b and
commercially available methyl 5-bromobutanoate (16c) in the presence
of K2CO3 to afford 17a-c, respectively, in good yields. Final PROTACs
18a-c were obtained upon deprotection of either the tert-butyl group, in
case of 17a-b, or the methyl group for 17c, and subsequent amide
coupling with CRBN ligand 3, using (1-cyano-2-ethoxy-2-ox-
oethylidenaminooxy)dimethylamino-morpholino-carbenium hexa-
fluorophosphate (COMU) as coupling reagent and N,N-diisopropy-
lethylamine (DIPEA) as base (Scheme 3).
2.4. Third series of PROTACs.
For the synthesis of this series of PROTACs, VHL ligand 20 was
synthesized in two steps: a first coupling reaction of previously reported
compound 19 (ref. 15) with 1-fluorocyclopropane-1-carboxylic acid,
followed by deprotection of the thiol moiety (Scheme 4). Linkers 16a-c
were connected to 20 via a sulphur alkylation reaction in the presence
of DBU as the base. Deprotection of the tert-butyl ester group of 21a-c,
and subsequent coupling with 3 under the same conditions described
above, delivered the final compounds 22a-c in good yields (Scheme 4).
2.5. Evaluation of PROTAC cellular activity.
To profile the degradation activity of our panel of PROTACs, VHL
and CBRN protein levels in HeLa cells were quantified by western blot
analysis following a 4 h treatment with 1 µM compounds, using CM11
and CC15a as positive controls for VHL and CRBN degradation, re-
spectively (Figure 4). Interestingly, we observed significant degradation
of CRBN with a few compounds, while no significant degradation of
VHL was observed with any of the compounds tested. The most pro-
found CRBN degradation was observed with PROTAC 14a (64% protein
degradation, as quantified by western blot), followed by compound 18b
which induced CRBN degradation to a lower extent (54% degradation).
The same screen was conducted in a different cell line (HEK293),
confirming 14a as the most potent compound at inducing CRBN de-
gradation (data not shown). To provide a more stringent screen the
Scheme 1. Synthesis of PROTACs 7a-b. Conditions: i. 1:1 TFA/DCM, r.t.; ii. HATU, HOAt, 3, DIPEA, DMF, r.t.
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same experiment was conducted by testing compounds at 10 nM in
HeLa cells (Figure S1). The purpose of this experiment was to exclude
the possibility of dismissing any potent compound as a false negative
potentially due to the “hook effect” characteristic of bivalent molecules:
whereby unproductive binary complexes preferentially form at high
PROTAC concentration, which compete with and eventually suppress
the formation of a productive ternary complex.9 PROTAC 14a induced
less CRBN degradation (19% protein degradation) at 10 nM compared
to 1 µM, as expected. Importantly, CRBN protein levels remaining after
treatment at 10 nM were not significantly lower than the levels re-
maining after the same treatment at 1 µM (cf. Figure S1 with Figure 4),
making it unlikely that any of the compounds might be false negatives
due to a hook effect. Interestingly, at this lower concentration some
compounds appeared to induce up to 50% degradation of pVHL30
(Figure S1). This suggests that depending on the concentration being
used this class of compounds could preferentially induced the depletion
of one ligase over the other.
Encouraged by the promising and consistent degradation of CRBN
observed with PROTAC 14a, we selected this compound for further
characterization. We next profiled the concentration- and time-depen-
dent activity of 14a in both HeLa (Figure 5) and HEK293 cells (Figure
S2). Compound 14a degraded CRBN with a half-degrading concentra-
tion DC50 (i.e. the concentration causing 50% reduction of protein level
relative to vehicle) of 200 nM, and reached a maximal degradation
(Dmax) of 75% after 4 h treatment with 1 µM. A hook effect was ob-






12a: A = -((CH2)5O(CH2)2O(CH2)5)-
12b: A = -((CH2)6)-
12c: A = -(CH2CH2(OCH2CH2)4)-
12d: A = -(CH2CH2(OCH2CH2)7)-


















































Scheme 2. Synthesis of PROTACs 14a-e. Reagents and conditions: i. NHS, DCC, DCM, r.t, overnight; ii. 3, DIPEA, DMF, r.t; iii. 1, COMU, DIPEA, DMF.
Scheme 3. Synthesis of PROTACs 18a-c. Reagents and conditions: i. Iodine, triphenylphosphine, imidazole, DCM, 0 °C; ii. 2, K2CO3, DMF, 70 °C, overnight, iii. for
tert-butyl deprotection: 1:1 TFA/DCM; for the methyl deprotection: LiOH in water/THF, 2 h, r.t; iv. COMU, 3, DIPEA, DMF, r.t.
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species (i.e. acts as inhibitor) at higher concentrations. Very similar
degradation profile and comparable DC50 and Dmax were found for 14a
in HEK293 (Figure S2). Again, some concentration-dependent depletion
of pVHL30 was seen at the lower end of the concentration range
(5–50 nM) in HeLa (Figure 5). However interestingly this effect was not
observed in HEK293 (Figure S2). From the time-course data, compound
14a was able to induce rapid degradation, with > 50% CRBN levels
relative to control depleted already after 1 h; maximal degradation >
80% was attained after 8 h (Figure 5). The 14a-induced degradation of
CRBN was found to be even faster in HEK293, with > 80% protein
already depleted after 1 h, and 98% degradation achieved after 8 h
(Figure S2). Once again the compound displayed selectivity for CRBN,
as there was no appreciable VHL degradation at 1 µM over the time
points tested in either cell line (Figure 5 and Figure S2).
3. Discussion
We described dually targeting CRBN-VHL PROTACs, developed
with the aim of investigating the relative ability of CRBN and VHL E3
ligase to induce degradation of one other. Among the three series of
compounds developed, we observed preferential degradation of one
ligase i.e. CRBN over the other one (VHL) with some of the compounds
from two of the series. The most potent PROTAC, compound 14a, in-
duced CRBN degradation with high potency (DC50 of 200 nM) and to
profound levels (Dmax of up to 98%) and rapidly (within 1 h of treat-
ment). Further structure-activity relationships could help to better un-
derstand and improve the already high potency and efficiency of CRBN
degradation achieved with 14a.
Our data thus suggests that VHL can ‘win the battle’ with CRBN
when the two ligases are brought together by a PROTAC. Future me-
chanistic studies are warranted to attempt to elucidate the contributors
for this preferential unilateral outcome of our ‘double-hijacking’ ap-
proach. We also cannot exclude that different combinations of con-
jugation patterns (via different attachment points for example) and
linker lengths and structures of CRBN-VHL PROTACs might be able to
discriminate different relative orientation of the ternary complex in
such a way that the outcome might become reverse, i.e. VHL being
preferentially degraded over CRBN – a hypothesis that will be tested in
future work. In this regard, it is interesting to note that minor con-
centration-dependent depletion of pVHL30 was observed at the lower
end of the concentration range (5–50 nM) in HeLa (Figure 5) as well as
in the screen at lower compound concentration (10 nM, Figure S2).
pVHL30 is the VHL isoform that is preferentially degraded by the homo-
PROTAC CM11.11 No observable PROTAC-induced degradation of
pVHL19 was instead observed with any of our compounds, consistent
with the cellular outcome observed with CM11. These observations
together suggest an enticing possibility that differential ligase de-
gradation might apply at distinct ranges of concentration of CRBN-VHL
dimerizers. Differential absolute concentration between the two E3
Scheme 4. Synthesis of PROTACs 22a-c. Reagents and conditions: i. 1-fluorocyclopropane-1-carboxylic acid, HATU, HOAt, DIPEA, DMF, r.t., 30min; ii. TIPS, TFA,
DCM, r.t., 2 h; iii. DBU, DMF, 0 °C to r.t, 4 h; iv. For tert-butyl deprotection: 1:1 TFA/DCM; for the methyl deprotection: LiOH in water/THF 2 h, r.t; v. COMU, 3,
DIPEA in DMF, r.t.
Figure 4. Screening of VHL-CRBN hetero-PROTACs. Western blot analysis of
CRBN and VHL levels following 4 h treatment of HeLa cells with 1 µM com-
pound. Values reported below each lane indicate protein abundance relative to
the average 0.1% DMSO vehicle, and normalized for loading control.
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ligases, and/or differential binding affinities of each end of the bivalent
molecule for its respective ligase, are likely to be amongst the con-
tributing factors that could effectively skew the hook effect towards one
ligase versus the other one depending on the PROTAC concentration,
ultimately imparting differential protein degradation outcomes. Such
an effect could be of relevance in a broader context for other E3 ligase
pairs. It is noteworthy that a recent study reported MDM2 PROTAC
degraders, designed by linking an MDM2 inhibitor via either a thali-
domide-based CRBN ligand or a VHL ligand.59 Potent and selective
PROTAC-induced degradation of MDM2 was observed for the CRBN-
MDM2 heterodimers. However notably, protein level of the hijacked
CRBN or VHL ligases were not monitored.59 Hetero-bifunctional VHL-
CRBN PROTACs were also disclosed in a study recently published by
Steinebach et al.60 Preferential degradation of CRBN over VHL was also
observed by Steinebach et al., with their most potent compound (CRBN-
6-5-5-VHL) being a conjugate of pomalidomide and VHL ligand via the
terminal acetyl group, as with 14a, albeit with a different linker
structure.60
Our study provides proof of principle for dimerizing two different
E3 ligases as a novel approach to inducing one ligase to degrade the
other one. The outcome of ‘ligase versus ligase’ PROTAC-mediated ac-
tivity might be unpredictable a priori, but could reveal a new me-
chanism for proximity-mediated hijacking between E3 ligases. Future
work is warranted to interrogate many more combinations of E3 ligases
and hetero-dimerizer compounds to bring E3 ligases together as a me-
chanism to induce their intracellular degradation. Given the number of
E3 ligases predicted to function in cells (up to 600) this approach could
speed up our ability to chemically intervene on E3 ligase themselves




Commercially available chemicals were purchased from Apollo
Scientific, Sigma-Aldrich, Fluorochem, or Manchester Organics and
used without any further purification. Compounds 1,8 2,23 3,23 6b,11
12e,11 and 19,15 were prepared as previously described.
All reactions were carried out using anhydrous solvents. Analytical
thin-layer chromatography (TLC) was performed on precoated TLC
plates (layer 0.20mm silica gel 60 with fluorescent indicator (UV 254:
Merck)). The TLC plates were air-dried and revealed under UV lamp
(254/365 nm) or permanganate stain. Flash column chromatography
was performed using prepacked silica gel cartridges (230–400 mesh,
40–63mm; SiliCycle) using a Teledyne ISCO Combiflash Companion or
Combiflash Retrieve using the solvent mixtures stated for each synthesis
as mobile phase. Preparative HPLC was performed on a Gilson pre-
parative HPLC with a Waters X-Bridge C18 column (100mm×19mm;
5 μm particle size, flow rate 25mL/min). Liquid chromatography–mass
spectrometry (LC–MS) analyses were performed with either an Agilent
HPLC 1100 series connected to a Bruker Daltonics MicroTOF or an
Agilent Technologies 1200 series HPLC connected to an Agilent
Technologies 6130 quadrupole spectrometer. For LC-MS the analytical
cololum used was a Waters X-bridge C18 column
(50mm×2.1mm×3.5mm particle size); flow rate, 0.5mL/min with
a mobile phase of water/MeCN+0.01% NH4OH (basic analytical
method) or water/MeCN+0.01% HCOOH (acidic analytical method);
95/5 water/MeCN was initially held for 0.5 min followed by a linear
gradient from 95/5 to 5/95 water/MeCN over 3.5 min which was then
held for 2min. The purity of all the compounds was evaluated using the
Figure 5. Compound 14a induces rapid de-
pletion of CRBN, but not of VHL. (A)
Western blot analysis of CRBN and VHL le-
vels following 4 h treatment of HeLa cells
with the indicated concentrations of 14a.
(B) Quantification of CRBN levels following
concentration-dependent assessment. (C)
Western blot analysis of CRBN and VHL le-
vels following treatment of HeLa cells with
1 µM 14a for the indicated time points. (D)
Quantification of CRBN levels following
time-dependent assessment. Values reported
below each lane indicate protein abundance
relative to the average 0.1% DMSO vehicle,
and normalized for loading control. DC50
and half-lives were determined as described
in the Experimental Section.
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analytical LC–MS system described before, and purity was >95%. 1H
NMR and 13C NMR spectra were recorded on a Bruker Avance II 500
spectrometer (1H at 500.1MHz, 13C at 125.8MHz) or on a Bruker DPX-
400 spectrometer (1H at 400.1MHz, 13C at 101MHz). Chemical shifts
(δ) are expressed in ppm reported using residual solvent as the internal
reference in all cases. Signal splitting patterns are described as singlet
(s), doublet (d), triplet (t), multiplet (m), or a combination thereof.
Coupling constants (J) are quoted to the nearest 0.1 Hz.
4.1.1. General method to obtain di-tert-butyl protected carboxylate (A):
To a solution of diol (1 eq.) in dichloromethane (DCM) (4mL per
mmol), tert-butyl bromoacetate (8 eq.), TBABr (1.1 eq.) and 37% w/w
aqueous NaOH (4mL per mmol) were added. The biphasic reaction was
vigorously stirred at room temperature (r.t.) overnight. The organic
phase was separated from the aqueous layer and then the aqueous
phase was extracted with DCM (x3). Organic layers were collected,
dried over MgSO4 and evaporated under reduced pressure. The crude
was purified by flash chromatography (using a gradient from 10 to
100% of ethyl acetate in heptane).
4.1.2. General method B:
A solution of the starting material in a 50% v/v trifluoroacetic acid
(TFA) in DCM (6mL per mmol) was stirred at r.t. for 2 h. TLC analysis
(10% methanol in DCM) showed complete conversion of the starting
material. Then, the reaction mixture was concentrated under reduced
pressure and the crude was freeze-dried to obtain the desired product.
4.1.3. General method C:
Potassium tert-butoxide (1 eq.) was added to polyethylene glycol
(8 eq.) in anhydrous THF (0.2 mL/mmol) at 0 °C. The resulting mixture
was stirred at 60 °C for 0.5 h, then it was cooled to r.t. A solution of tert-
butyl-bromoacetate (1.0 eq.) in anhydrous THF (0.1mL/mmol) was
added to the reaction mixture at r.t. The resulting mixture was stirred at
r.t. for 24 h. The reaction was quenched with brine and the aqueous
phase was extracted with ethyl acetate. The combined organic phase
was evaporated to dryness. The crude material was purified by column
chromatography (from 0 to 8% of methanol in DCM) to afford the de-
sired compound.
4.1.4. General method D:
Iodine (1.3 eq.) was added to triphenylphosiphine (1.3 eq.) and
imidazole (1.3 eq.) in DCM (7mL/mmol) at 0 °C. The resulting mixture
was stirred at r.t. for 5min, then was cooled to 0 °C. A solution of al-
cohol (1.0 eq.) in DCM (3mL/mmol) was added to the reaction mixture
at 0 °C and the resulting mixture was stirred at r.t. for 3 h. TLC analysis
(50% ethyl acetate in heptane) showed complete conversion of the
starting material. The reaction was quenched with saturated NaHCO3
solution and saturated Na2SO3 solution and the aqueous phase was
extracted with ethyl acetate. The combined organic phase was evapo-
rated to dryness. The crude material was purified by column chroma-
tography (from 20 to 75% of ethyl acetate in heptane) to afford the
desired compound.
4.1.5. General method E:
The dicarboxylic acid linker (1 eq.) and NHS (1.1 eq.) were dis-
solved in dry DCM (∼10mL per mmol). DCC (1.2 eq.) was added and
the reaction was left to stir overnight. The DCU was filtered off, the
solution was evaporated and the residue dissolved in dry DMF.
Compound 3 (0.5 eq.) and DIPEA (3 eq.) were added. The reaction
mixture was left to stir at r.t. for 2 h, quenched with ice, dried under
high vacuum and purified by HPLC using a gradient from 10% to 80%
v/v acetonitrile with 0.01% v/v aqueous solution of formic acid over
15min to yield the desired compound.
4.1.6. General method F:
To a solution of carboxylic compound (1 eq.) in dry DMF (∼50mL
per mmol), COMU (1 eq.), compound 1 (1.1 eq.) and DIPEA (3 eq.) were
added. The reaction mixture was left to stir for 1 h and monitored by
LC-MS (acidic method). When completed, ice was added to quench the
reaction, the volatiles were evaporated under reduced pressure and the
residue purified by HPLC with a gradient from 5% to 90% v/v acet-
onitrile with 0.01% v/v aqueous solution of formic acid over 15min to
yield the desired compound.
4.1.7. General method G:
To a solution of 20 (1 eq.) and the linker (1.1 eq.) in dry DMF
(∼14mL per mmol), DBU (1.1 eq.) was added at 0 °C under a nitrogen
atmosphere. The reaction mixture was stirred at r.t. for 4 h and mon-
itored by LC-MS (acidic method). The reaction was quenched with a 5%
v/v aqueous solution of citric acid and the solvent was evaporated
under high vacuum. The crude was purified by HPLC using a gradient
from 5% to 90% v/v acetonitrile with 0.01% v/v aqueous solution of
formic acid over 15min to yield the desired compound.
4.1.8. General method H:
To a solution of the carboxylic compound (1 eq.) in dry DMF
(∼100mL per mmol), COMU (1 eq.), compound 3 (1.1 eq.) and DIPEA
(3 eq.) were added. The reaction mixture was left to stir for 1 h and
monitored by LC-MS (acidic method). Then, ice was added to quench
the reaction, the volatiles were evaporated under reduced pressure and
the residue purified by HPLC using a gradient from 5% to 90% v/v
acetonitrile with 0.01% v/v aqueous solution of formic acid over
15min to yield the desired compound.
4.1.9. General method I:
Compound 2 (1 eq.), K2CO3 (3 eq.) and the halogenated linker
(1.5 eq.) was dissolved in DMF (∼50mL per mmol) and heated at 70 °C
overnight. Complete conversion of the starting material was observed
by LC-MS (acidic method). The reaction mixture was taken up with
water and extracted with DCM (x3). Organic layers were collected,
dried over MgSO4, evaporated under reduced pressure and purified by
HPLC using a gradient from 5% to 95% acetonitrile with 0.01% v/v





To a solution of compound 5a (59.83mg, 0.22mmol, 1 eq.), in
1.5 mL DMF, HATU (81.74mg, 0.22mmol, 1 eq.), HOAT (29.26mg,
0.22mmol, 1 eq.) were added and the solution was stirred at r.t. for
5min. Compound 1 (100mg, 0.215mmol, 1 eq.) was added and the pH
of the reaction mixture was adjusted to > 9 by addition of DIPEA (∼3
eq.). The mixture was stirred at r.t. until no presence of the starting
materials was detected by LC-MS (acidic method). Water was added
and the mixture was extracted with ethyl acetate (×3). The combined
organic phases were washed with brine (×2), dried over MgSO4 and
evaporated under reduced pressure to give the corresponding crude
which was purified by HPLC using a gradient of 20% to 95% v/v
acetonitrile in 0.01% aqueous solution of ammonia over 10min to yield
the final compound (72.8 mg, yield: 51%). 1H NMR (400MHz, CDCl3) δ
8.94 (s, 1H), 7.42–7.36 (m, 1H), 7.32–7.20 (m, 5H), 4.67–4.63 (m, 1H),
4.53–4.42 (m, 3H), 4.31–4.25 (m, 1H), 4.01–3.87 (m, 5H), 3.64–3.55
(m, 18H), 2.47–2.34 (m, 4H), 2.11–2.04 (m, 1H), 1.40 (s, 9H), 0.91 (s,
9H); 13C NMR (126MHz, CDCl3) δ 171.3, 171.1, 170.5, 170.0, 151.7,
139.1, 129.4, 128.3, 82.0, 71.1, 70.6, 70.4, 70.3, 70.2, 68.9, 58.7, 57.3,
56.8, 43.1, 36.3, 35.1, 28.1, 26.4, 15.1. MS: calculated for:
C34H51N4O9S2 [M+H]+: m/z=691.3; observed: m/z=691.4.






Following general method B from compound 6a (72.3mg,
0.11mmol, 1 eq.), the carboxylic acid derivative was obtained as an oil.
The compound was used for the next step without further purification.
Yield: 99.3mg, 0.11mmol (quantitative). MS (ESI) m/z: [M+H]+
calculated for: C30H42N4O9S: 634.27; observed: 635.3.
To a solution of the crude carboxylic acid (21.16mg, 0.028mmol,1
eq.) in DMF (0.5 mL) was added HATU (10.64mg, 0.028mmol, 1 eq.)
and HOAT (3.81mg, 0.028mmol, 1 eq.). The resulting mixture was
stirred at r.t. for 5min. Compound 3 (10mg, 0.028mmol, 1 eq.) was
added and the pH of the reaction mixture was adjusted to > 9 by
addition of DIPEA (∼3 eq.). The mixture was stirred at r.t. until no
presence of the starting materials was detected by LC-MS. The solvent
was evaporated under reduced pressure to give the corresponding crude
which was purified by HPLC using a gradient of 5% to 95% v/v acet-
onitrile with 0.01% aqueous solution of formic acid over 15min to yield
the final compound as a yellow solid. Yield: 25mg, 0.026mmol (95%).
1H NMR (500MHz, CDCl3) δ 8.62 (s, 0.5H), 8.61 (s, 0.5H), 7.60–7.54
(m, 1H), 7.48–7.38 (m, 2H), 7.30–7.25 (m, 4H), 7.01 (d, J = 7.4 Hz,
1H), 6.90 (d, J = 8.4 Hz, 1H), 6.41–6.34 (m, 1H), 4.83–4.78 (m, 1H),
4.59–4.50 (m, 2H), 4.48–4.44 (m, 1H), 4.26–4.21 (m, 1H), 3.97–3.81
(m, 5H), 3.63–3.40 (m, 12H), 2.67 (t, J = 4.7 Hz, 3H), 2.44 (d,
J = 1.8 Hz, 3H), 2.35–2.29 (m, 1H), 2.12–2.05 (m, 1H), 2.03–1.97 (m,
2H), 0.89 (s, 9H); 13C NMR (126MHz, CDCl3) δ172.2, 171.4, 171.3,
171.3, 170.9, 170.8, 170.3, 170.2, 169.4, 169.2, 169.1, 167.6, 150.4,
150.4, 148.4, 148.4, 146.8, 146.8, 138.5, 138.5, 136.2, 132.5, 132.5,
131.7, 131.7, 130.7, 130.7, 129.4, 129.3, 128.1, 116.7, 111.8, 111.8,
110.3, 110.2, 71.1, 70.9, 70.8, 70.3, 70.2, 70.2, 70.1, 60.4, 59.0, 59.0,
57.0, 56.9, 56.8, 50.7, 48.9, 48.9, 43.1, 41.7, 38.8, 38.6, 36.6, 35.6,
35.5, 31.5, 26.5, 26.3, 22.7, 22.7, 16.0, 14.2. HRMS: calculated for:





To a solution of the Boc-deprotected carboxylic acid derivative of
compound 6b (obtained as described in ref.11) (23.88mg, 0.028mmol,
1 eq.) in dry DMF (0.5mL), HATU (10.64mg, 0.028mmol, 1 eq.) and
HOAT (3.81mg, 0.028mmol, 1 eq.) were added. The solution was
stirred for 5min, compound 3 (10mg, 0.028mmol, 1 eq.) was added
and the pH of the reaction was adjusted to >9 with DIPEA. The mix-
ture was stirred at r.t. until no presence of the starting materials was
detected by LC-MS. Water was added and the mixture was extracted
with ethyl acetate (×3). The combined organic phases were washed
with brine (×2), dried over MgSO4 and evaporated under reduced
pressure to give the corresponding crude, which was purified by HPLC
using a gradient of 20% to 95% v/v acetonitrile with 0.01% aqueous
solution of ammonia over 10min to yield the final compound as a white
solid (24mg, yield: 84%). 1H NMR (500MHz, CDCl3) δ 8.70 (s, 0.5H),
8.69 (s, 0.5H), 7.64–7.58 (m, 1H), 7.55–7.49 (m, 1H), 7.43–7.40 (m,
1H), 7.32–7.27 (m, 5H), 7.02–6.95 (m, 2H), 4.84–4.77 (m, 1H),
4.66–4.59 (m, 1H), 4.56–4.48 (m, 2H), 4.28–4.23 (m, 1H), 3.95–3.82
(m, 4H), 3.63–3.36 (m, 22H), 2.46–2.44 (m, 4H), 2.41–2.34 (m, 1H),
2.14–2.08 (m, 1H), 0.90 (s, 9H); 13C NMR (126MHz, CDCl3) δ: 171.3,
171.2, 171.1, 170.5, 170.3, 169.4, 168.9, 167.6, 150.7, 150.6, 147.9,
146.8, 146.8, 138.7, 138.6, 136.2, 132.5, 132.0, 130.5, 130.4, 129.4,
129.3, 128.2, 117.0, 111.7, 110.1, 70.9, 70.6, 70.5, 70.4, 70.3, 70.2,
70.1, 70.0, 59.0, 58.8, 57.0, 56.9, 48.9, 43.2, 41.9, 38.4, 38.3, 36.5,
35.4, 35.3, 31.5, 26.4, 22.7, 15.8. HRMS calculated for: C49H65N8O14S
[M+H]+: m/z=1021.4335; observed: m/z=1021.4546 [M+H]+.
4.1.13. 3,9,12,18-tetraoxaicosanedioic acid (12a)
Starting from compound 11a (83mg, 0.17mmol) and following the
general method B compound 12a was obtained in quantitative yield
(64mg). 1H NMR (500MHz, CDCl3) δ: 8.06 (s, 2H), 4.09 (s, 4H), 3.59
(s, 4H), 3.56 (t, J=6.5 Hz, 4H), 3.49 (t, J=6.5 Hz, 4H), 1.66–1.58 (m,
8H), 1.47–1.41 (m, 4H); 13C NMR (101MHz, CDCl3) δ: 174.4, 72.0,
71.4, 70.1, 67.9, 29.2, 29.1, 22.6.
4.1.14. 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-
4-oxo-6,12,15,21-tetraoxa-3-azatricosan-23-oic acid (13a)
Starting from compound 12a (36mg, 0.098mmol,1 eq) and fol-
lowing the general method E, the title compound was obtained
(14mg, yield: 44%). 1H NMR (500MHz, CDCl3) δ: 7.48 (dd, J=7.2,
8.6 Hz, 1H), 7.09 (d, J=7.1 Hz, 1H), 6.98 (d, J=8.9 Hz, 1H),
4.93–4.89 (m, 1H), 4.04 (s, 2H), 3.93 (s, 2H), 3.55–3.41 (m, 16H),
2.88–2.66 (m, 3H), 2.13–2.06 (m, 1H), 1.64–1.52 (m, 8H), 1.46–1.32
(m, 4H); 13C NMR (126MHz, CDCl3) δ: 172.4, 171.7, 171.4, 169.5,
168.8, 167.7, 146.9, 136.4, 132.7, 116.9, 112.1, 110.7, 71.9, 71.3,
71.2, 70.3, 70.2, 68.1, 49.1, 42.3, 38.6, 31.6, 29.4, 29.3, 22.9, 22.7. MS:






Starting from compound 13a (14mg, 0.02mmol, 1 eq.) and fol-
lowing the general method F, the title compound was obtained
(12mg, yield: 52%). 1H NMR (400MHz, MeOD) δ: 9.00 (s, 1H),
7.56–7.52 (m, 1H), 7.48–7.41 (m, J=8.5, 20.5 Hz, 4H), 7.14 (d,
J=8.5 Hz, 1H), 7.05 (d, J=7.5 Hz, 1H), 5.05 (dd, J=5.2, 12.7 Hz,
1H), 4.70 (d, J=10.3 Hz, 1H), 4.60–4.50 (m, 3H), 4.36 (d,
J=16.0 Hz, 1H), 3.96 (d, J=6.9 Hz, 2H), 3.91–3.78 (m, 4H), 3.47 (m,
J=7.9, 28.1 Hz, 16H), 2.90–2.64 (m, 3H), 2.48 (s, 3H), 2.26–2.21 (m,
1H), 2.12–2.05 (m, 2H), 1.68–1.33 (m, 12H), 1.03 (s, 9H); 13C NMR
(101MHz, MeOD) δ: 174.5, 174.2, 173.4, 172.0, 171.9, 171.6, 171.4,
170.5, 169.1, 153.1, 148.2, 148.0, 140.4, 137.1, 133.8, 133.7, 131.0,
130.3, 129.4, 128.9, 118.0, 112.0, 111.3, 72.7, 72.6, 72.0, 71.0, 70.8,
70.6, 66.8, 60.7, 58.0, 57.9, 43.6, 42.6, 39.3, 38.8, 37.1, 32.1, 30.3,
30.1, 26.8, 23.7, 23.6, 15.5, 15.3. HRMS: calculated for C53H73N8O13S
[M+H]+: m/z=1061.5012; observed: m/z=1061.5065.
4.1.16. 2,2′-(hexane-1,6-diylbis(ox))diacetic acid (12b)
Starting from compound 11b (185mg, 0.53mmol) and following
the general method B compound 12b was obtained in quantitative
yield (125mg). 1H NMR (400MHz, DMSO) δ: 12.49 (s, 2H), 3.97 (s,
4H), 3.43 (t, J=6.6 Hz, 4H), 1.55–1.47 (m, 4H), 1.34–1.28 (m, 4H);
13C-NMR (101MHz, DMSO) δ 171.6, 70.4, 67.4, 29.0, 25.3.
4.1.17. 2-((6-(2-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)amino)ethyl)amino)-2-oxoethoxy)hexyl)oxy)acetic acid (13b)
To a solution of compound 12b (15.0mg, 0.064mmol, 1 eq.) and
following the general method E, the title compound was obtained
(7mg, yield: 41%). 1H NMR (400MHz, MeOD) δ: 7.56 (dd, J=7.1,
8.6 Hz, 1H), 7.15 (d, J=8.6 Hz, 1H), 7.07 (d, J=7.1 Hz, 1H), 5.05
(dd, J=5.5, 12.5 Hz, 1H), 4.02 (s, 2H), 3.90 (s, 2H), 3.52–3.45 (m,
8H), 2.91–2.67 (m, 3H), 2.15–2.08 (m, 1H), 1.63–1.55 (m, 4H),
1.38–1.34 (m, 4H); 13C NMR (126MHz, MeOD) δ: 174.6, 174.1, 173.5,
171.5, 170.6, 169.3, 148.2, 137.2, 134.0, 118.1, 112.1, 111.5, 72.8,
72.6, 70.9, 68.7, 42.7, 39.4, 32.2, 30.4, 26.8, 23.8. MS: calculated for
C25H33N4O9 [M+H]+ : m/z=532.2 ; observed: m/z=533.3.






Starting from compound 13b (7 mg, 0.013mmol, 1 eq) and fol-
lowing the general method F, the title compound was obtained
(7.7 mg, yield: 62%). 1H NMR (400MHz, MeOD) δ: 8.99 (s, 1H),
7.56–7.49 (m, 1H), 7.44 (dd, J=7.9, 21.3 Hz, 4H), 7.11 (d, J=8.9 Hz,
1H), 7.05 (d, J=7.0 Hz, 1H), 5.04 (dd, J=5.6, 12.6 Hz, 1H),
4.71–4.68 (m, 1H), 4.61–4.33 (m, 4H), 3.95 (d, J=6.3 Hz, 2H),
3.91–3.78 (m, 4H), 3.54–3.42 (m, 8H), 2.85–2.63 (m, 3H), 2.48 (s, 3H),
2.26–2.21 (m, 1H), 2.10–2.07 (m, 2H), 1.63–1.56 (m, 4H), 1.40–1.31
(m, 4H), 1.03 (s, 9H). 13C-NMR (101MHz, MeOD) δ: 174.4, 174.1,
173.3, 171.8, 171.5, 171.3, 170.4, 169.0, 153.0, 148.0, 140.3, 137.0,
133.8, 130.9, 130.2, 128.9, 117.9, 112.0, 111.2, 72.7, 72.5, 70.9, 70.7,
70.5, 60.6, 57.9, 57.8, 43.5, 42.5, 39.2, 38.7, 37.0, 32.0, 30.3, 30.2,
26.7, 26.6, 23.6, 15.2. HRMS: calculated for C47H61N8O11S [M+H]+:
m/z=945.4175; observed: m/z=945.4270.
4.1.19. 3,6,9,12,15,18-hexaoxaicosanedioic acid (12c)
Starting from compound 11c (300mg, 0.64mmol) and following
the general method B compound 12c was obtained in quantitative
yield (226mg). Analytical data matched those previously reported.61
4.1.20. 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-
4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosan-23-oic acid (13c)
Starting from compound 12c (23mg, 0.065mmol, 1 eq.) and fol-
lowing the general method E, the title compound was obtained
(5.9 mg, 28%). 1H NMR (400MHz, CDCl3) δ: 7.49 (t, J=7.8 Hz, 1H),
7.08 (d, J=6.8 Hz, 1H), 7.03 (d, J=8.4 Hz, 1H), 4.93–4.86 (m, 1H),
4.10 (s, 2H), 3.97 (s, 2H), 3.72–3.45 (m, 24H), 2.89–2.65 (m, 3H),
2.13–2.07 (m, 1H); 13C NMR (126MHz, CDCl3) δ :172.5, 171.4, 171.3,
169.4, 168.7, 167.8, 147.0, 136.4, 132.7, 117.0, 111.9, 110.5, 71.0,
70.5, 70.4, 70.3, 70.2, 69.4, 49.1, 42.0, 38.5, 31.6, 22.9. MS: calculated





Starting from compound 13c (5.9mg, 0.0090mmol, 1 eq.) and
following the general method F, the title compound was obtained
(4mg, yield: 42%). 1H NMR (400MHz, MeOD) δ: 8.86 (s, 1H), 7.55 (dd,
J=7.1, 8.5 Hz, 1H), 7.44 (dd, J=8.2, 18.7 Hz, 4H), 7.14 (d,
J=8.5 Hz, 1H), 7.05 (d, J=7.1 Hz, 1H), 5.04 (dd, J=5.6, 12.8 Hz,
1H), 4.70 (s, 1H), 4.61–4.48 (m, 3H), 4.35 (d, J=14.2 Hz, 1H), 4.03
(d, J=4.4 Hz, 2H), 3.95 (s, 2H), 3.90–3.77 (m, 2H), 3.71–3.58 (m,
20H), 3.52–3.49 (m, 4H), 2.89–2.65 (m, 3H), 2.47(s, 3H), 2.26–2.18
(m, 1H), 2.14–2.05 (m, 2H), 1.04 (s, 9H).13C-NMR (101MHz, MeOD) δ
174.7, 174.4, 173.6, 172.1, 171.7, 171.5, 170.6, 169.3, 152.8, 149.1,
148.2, 140.3, 137.3, 134.0, 133.4, 131.6, 130.4, 129.0, 118.2, 112.1,
111.5, 72.3, 72.0, 71.7, 71.6, 71.5, 71.3, 71.1, 60.8, 58.2, 58.1, 43.8,
42.5, 39.4, 38.9, 37.1, 32.2, 27.0, 23.8, 15.9. HRMS: calculated for
C51H72N9O15S [M+NH4]+: m/z=1082.4863; observed: m/
z=1082.4790.
4.1.22. 3,6,9,12,15,18,21,24,27-nonaoxanonacosanedioic acid (12d)
Starting from compound 11d (100mg, 0.17mmol) and following
the general method B compound 12d was obtained in quantitative





Starting from compound 12d (4.6 mg, 0.010mmol, 1 eq.) and
following the general method E, the title compound was obtained
(8.5mg, yield: 22%). 1H NMR (500MHz, CDCl3) δ: 7.49 (dd, J=7.2,
8.5 Hz, 1H), 7.08 (d, J=7.1 Hz, 1H), 7.02 (d, J=8.6 Hz, 1H), 4.89
(dd, J=5.5, 12.3 Hz, 1H), 4.12 (s, 2H), 3.98 (s, 2H), 3.72–3.48 (m,
36H), 2.89–2.69 (m, 3H), 2.12–2.08 (m, 1H); 13C NMR (126MHz,
CDCl3) δ: 172.1, 171.4, 169.4, 168.6, 167.7, 147.0, 136.4, 132.7, 117.0,
111.9, 110.5, 71.1, 70.8, 70.7, 70.6, 70.5, 70.4, 70.2, 69.3, 49.1, 42.1,






Starting from compound 13d (8.5mg, 0.0108mmol, 1 eq.) and
following the general method F, the title compound was obtained
(7.0mg, yield: 54%). 1H NMR (500MHz, MeOD) δ: 8.87 (s, 1H), 7.55
(dd, J=7.2, 8.6 Hz, 1H), 7.44 (dd, J=8.6, 22.4 Hz, 4H), 7.15 (d,
J=8.4 Hz, 1H), 7.06 (d, J=7.0 Hz, 1H), 5.04 (dd, J=5.2, 12.4 Hz,
1H), 4.70 (d, J=9.4 Hz, 1H), 4.60–4.50 (m, 3H), 4.36 (dd, J=4.9,
15.8 Hz, 1H), 4.04 (d, J=6.1 Hz, 2H), 3.96 (s, 2H), 3.89–3.79 (m, 2H),
3.71–3.51 (m, 36H), 2.88–2.66 (m, 3H), 2.47 (s, 3H), 2.24–2.20 (m,
1H), 2.12–2.07 (m, 2H), 1.04 (s, 9H); 13C-NMR (126MHz, MeOD) δ:
174.6, 174.3, 173.5, 172.1, 171.7, 171.4, 170.6, 169.2, 152.8, 149.1,
148.2, 140.3, 137.3, 134.0, 133.4, 131.5, 130.5, 130.4, 129.5, 129.0,
118.2, 112.1, 111.5, 72.3, 72.0, 71.6, 71.5, 71.4, 71.3, 71.1, 71.0, 60.8,
58.1, 43.7, 42.5, 39.4, 38.9, 37.1, 32.2, 27.0, 23.8, 15.8. HRMS: cal-




Starting from compound 12e (26.6mg, 0.10mmol, 1 eq.) and fol-
lowing the general method E, the title compound was obtained
(12.5 mg, 44%). 1H NMR (400MHz, CDCl3) δ: 7.47 (dd, J=7.2, 8.5 Hz,
1H), 7.06 (d, J=7.2 Hz, 1H), 7.01 (d, J=8.5 Hz, 1H), 4.90 (dd,
J=5.6, 11.7 Hz, 1H), 4.08 (s, 2H), 3.99 (s, 2H), 3.72–3.47 (m, 16H),
2.87–2.70 (m, 3H), 2.13–2.05 (m, 1H); 13C NMR (126MHz, CDCl3) δ:
172.6, 171.7, 171.4, 169.5, 169.0, 167.7, 147.0, 136.4, 132.6, 117.1,
111.9, 110.4, 71.1, 71.0, 70.5, 70.3, 69.0, 49.1, 42.1, 38.5, 31.6, 22.9.






Starting from compound 13e (12.5mg, 0.022mmol, 1 eq.) and
following the general method F, the title compound was obtained
(9.5mg, yield: 44%). 1H NMR (400MHz, MeOD) δ: 8.87 (s, 1H), 7.54
(dd, J=7.1, 8.4 Hz, 1H), 7.42 (dd, J=8.3, 20.1 Hz, 4H), 7.12 (d,
J=8.4 Hz, 1H), 7.04 (d, J=7.1 Hz, 1H), 5.03 (dd, J=5.5, 12.6 Hz,
1H), 4.70 (d, J=7.1 Hz, 1H), 4.61–4.48 (m, 3H), 4.35 (d, J=15.3 Hz,
1H), 4.03 (d, J=3.2 Hz, 2H), 3.94 (s, 2H), 3.88–3.78 (m, 2H),
3.70–3.49 (m, 16H), 2.89–2.66 (m, 3H), 2.46 (s, 3H), 2.25–2.20 (m,
1H), 2.13–2.06 (m, 2H), 1.03 (s, 9H). 13C NMR (101MHz, MeOD) δ:
174.7, 174.4, 173.6, 172.0, 171.7, 171.5, 170.6, 169.3, 152.8, 149.0,
148.2, 140.3, 137.3, 134.0, 133.4, 131.5, 130.4, 129.0, 112.2, 111.5,
72.2, 72.0, 71.5, 71.4, 71.3, 71.1, 60.8, 58.1, 43.8, 42.5, 39.5, 38.9,
37.1, 32.2, 27.0, 23.8, 15.8. HRMS: calculated for C47H61N8O13S
[M+H]+: m/z=977.4073; observed: m/z=977.4079.
4.1.27. Tert-butyl-2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate (15a)
Starting from triethylene glycol (6.9 g, 41mmol) and following the
general method C, the title compound was obtained (540mg, yield:
40%). 1H NMR (500MHz, MeOD) δ: 4.02 (s, 2H), 3.69–3.61 (m, 10H),
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3.55 (t, J=4.9 Hz, 2H), 1.48 (s, 9H). Analytical data matched those
previously reported.31
4.1.28. Tert-butyl-2-(2-(2-(2-iodoethoxy)ethoxy)ethoxy)acetate (16a)
Starting from compound 15a (350mg, 1.33mmol) and following
the general method D, the title compound was obtained. Yield: 414mg
(79%). 1H NMR (400MHz, CDCl3) δ: 4.06 (s, 2H), 3.81–3.70 (m, 10H),
3.28 (t, J=6.9 Hz, 2H), 1.50 (s, 9H). 13C NMR (101MHz, CDCl3) δ:





Starting from compound 2 (40mg, 0.075mmol, 1 eq.), 16a (42mg,
0.11mmol, 1.5 eq.) and K2CO3 (31mg, 0.22, 3 eq.), and following the
general method I, the titled compound was obtained (13mg, yield:
22%). 1H NMR (500MHz, CDCl3) δ: 8.66 (s, 1H), 7.00 (dd, J=3.4,
8.9 Hz, 1H), 6.95 (dd, J=1.6, 7.6 Hz, 1H), 6.88 (d, J=1.6 Hz, 1H),
4.65 (t, J=8.0 Hz, 1H), 4.53–4.44 (m, 4H), 4.24–4.14 (m, 2H),
4.00–3.59 (m, 14H), 2.50 (s, 3H), 2.42–2.36 (m, 1H), 2.13–2.08 (m,
1H), 1.44 (s, 9H), 1.32–1.22 (m, 4H), 0.94 (s, 9H); 13C NMR (126MHz,
CDCl3) δ: 170.8, 170.7, 170.1 (d, 2J=20.4 Hz), 169.8, 157.0, 150.4,
148.7, 132.5, 131.9, 130.0, 127.1, 122.2, 113.0, 81.8, 79.5, 70.9, 70.7,
70.4, 69.8, 69.2, 68.1, 58.8, 57.6, 56.7, 39.3, 36.6, 35.7, 28.3, 26.5,
16.3, 13.8 (d, 2J=5.2 Hz), 13.7 (d, 2J=5.2 Hz). MS: calculated for






Starting from compound 17a (13mg, 0.0167mmol) and following
the general method B the deprotected carboxylic acid derivative was
obtained in quantitative yield (12mg). Starting from the crude car-
boxylic acid (0.0166mmol, 1 eq.) and following the generalmethod H,
the desired compound was obtained (4mg, yield: 23%). 1H NMR
(500MHz, CDCl3) δ: 8.65 (s, 1H), 7.47–7.43 (m, 1H), 7.32–7.29 (m,
1H), 7.06 (dd, J=2.4, 7.2 Hz, 1H), 6.99–6.94 (m, 2H), 6.88–6.86 (m,
1H), 4.90–4.79 (m, 1H), 4.65–4.59 (m, 1H), 4.56 (t, J=9.0 Hz, 1H),
4.49–4.39 (m, 3H), 4.22–4.11 (m, 2H), 3.96–3.43 (m, 18H), 2.84–2.61
(m, 3H), 2.50 (d, J=2.7 Hz, 3H), 2.38–2.30 (m, 1H), 2.14–2.04 (m,
2H), 1.37–1.18 (m, 4H), 0.96 (d, J=1.8 Hz, 9H); 13C-NMR (126MHz,
CDCl3) δ: 171.3, 171.1, 171.0, 170.9, 170.3 170.1, 169.5, 169.0, 168.8,
167.7, 156.8, 150.4, 148.7, 146.9, 136.3, 132.7, 132.5, 131.8, 130.0,
129.8, 127.1, 127.0, 122.3, 122.2, 116.9, 113.0, 112.9, 112.0, 110.5,
79.6, 71.0, 70.8, 70.7, 70.5, 70.3, 70.2, 69.8, 68.1, 59.0, 58.9, 57.6,
56.8, 49.1, 49.1, 42.1, 39.2, 39.2, 38.7, 38.7, 36.8, 35.7, 35.6, 31.6,
26.5, 23.0, 22.9, 16.3, 13.9 (d, 2J=10.0 Hz),13.8 (d, 2J=10.0 Hz).
HRMS: calculated for C49H62FN8O13S[M+H]+: m/z=1021.4136;
observed: m/z=1021.4480.
4.1.31. Tert-butyl-17-hydroxy-3,6,9,12,15-pentaoxaheptadecanoate (15b)
Starting from pentaethylene glycol (7.32 g, 31mmol) and following
the general method C, the title compound was obtained. Yield: 600mg
(44%). Analytical data matched with those previously reported.31
4.1.32. Tert-butyl-17-iodo-3,6,9,12,15-pentaoxaheptadecanoate (16b)
Starting from compound 15b (400mg, 1.14mmol) and following
the general method D, the title compound was obtained. Yield: 402mg
(81%). 1H NMR (500MHz, CDCl3) δ: 4.05 (s, 2H), 3.81–3.69 (m, 18H),
3.29 (t, J=6.9 Hz, 2H), 1.50 (s, 9H). 13C NMR (126MHz, CDCl3) δ:





Starting from compound 2 (40mg, 0.075mmol, 1 eq.), 16b (42mg,
0.09mmol, 1.2 eq.) and K2CO3 (31mg, 0.22, 3 eq.), and following the
general method I, the titled compound was obtained (29mg, yield:
48%). 1H NMR (500MHz, CDCl3) δ: 8.64 (s, 1H), 7.02 (dd, J=3.6,
8.8 Hz, 1H), 6.94 (dd, J=1.6, 7.7 Hz, 1H), 6.87 (d, J=1.4 Hz, 1H),
4.63 (t, J=8.1 Hz, 1H), 4.54–4.42 (m, 4H), 4.22–4.12 (m, 2H), 3.97 (s,
2H), 3.93–3.83 (m, 3H), 3.75–3.60 (m, 17H), 2.49 (s, 3H), 2.39–2.33
(m, 1H), 2.10–2.06 (m, 1H), 1.43 (s, 9H), 1.31–1.20 (m, 4H), 0.93 (s,
9H); 13C NMR (101MHz, CDCl3) δ: 170.8, 170.7, 170.0 (d,
2J=20.3 Hz), 169.8, 157.0, 150.4, 148.6, 132.4, 131.8, 129.9, 127.1,
122.1, 113.0, 81.7, 79.5, 70.9, 70.7, 70.3, 69.8, 69.2, 68.1, 58.8, 57.5,
56.7, 39.2, 36.6, 35.8, 28.2, 26.5, 16.2, 13.7 (t, 2J=9.6 Hz). MS: cal-







Starting from compound 17b (29mg, 0.033mmol) and following
the general method B the deprotected carboxylic acid derivative was
obtained in quantitative yield (27mg). Starting from the crude car-
boxylic acid (27mg, 0.033, 1 eq.) and following the generalmethod H,
the desired compound was obtained (4.2mg, yield: 11%). 1H NMR
(500MHz, CDCl3) δ: 8.65 (s, 1H), 7.47 (t, J=7.6 Hz, 1H), 7.31 (d,
J=7.6 Hz, 1H), 7.07 (dd, J=1.4, 7.0 Hz, 1H), 7.00 (dd, J=1.4,
8.5 Hz, 1H), 6.94 (d, J=7.6 Hz, 1H), 6.87 (d, J=1.5 Hz, 1H),
4.90–4.82 (m, 1H), 4.63 (dt, J=3.2, 7.8 Hz, 1H), 4.55 (d, J=9.1 Hz,
1H), 4.50–4.42 (m, 3H), 4.21–4.10 (m, 2H), 3.95 (s, 2H), 3.95–3.43 (m,
24H), 2.92–2.62 (m, 3H), 2.50 (s, 3H), 2.39–2.31 (m, 1H), 2.15–2.04
(m, 2H), 1.35–1.18 (m, 4H), 0.94 (d, J=1.8 Hz, 9H). 13C NMR
(500MHz, CDCl3) δ: 171.4, 171.3, 171.2, 170.9, 170.8,
170.1(d,2J=20.5 Hz), 169.5, 168.8, 168.7, 167.7, 157.0, 150.4, 148.7,
147.0, 136.3, 132.7, 132.4, 131.8, 130.1, 127.1, 122.2, 117.0, 113.0,
111.9, 110.5, 79.3, 71.1, 70.9, 70.7, 70.6, 70.5, 70.5, 70.2, 69.8, 68.2,
58.9, 57.6, 56.8, 49.1, 42.1, 39.2, 38.6, 36.8, 35.7, 31.6, 26.5, 22.9,
16.3, 13.8 (d,2J=10.2 Hz), 13.7 (d,2J=10.2 Hz) HRMS: calculated for





Starting from compound 2 (40mg, 0.075mmol, 1 eq.), methyl 5-
bromobutanoate 16c (21mg, 0.113mmol, 1.5 eq.) and K2CO3 (31mg,
0.22, 3 eq.), and following the general method I, the titled compound
was obtained (30mg, yield: 62%). 1H NMR (500MHz, CDCl3) δ: 8.66 (s,
1H), 7.03 (dd, J=3.5, 8.8 Hz, 1H), 6.92 (dd, J=1.5, 7.7 Hz, 1H), 6.82
(d, J=1.5 Hz, 1H), 4.69 (t, J=7.8 Hz, 1H), 4.54–4.45 (m, 3H), 4.38
(dd, J=5.5, 14.9 Hz, 1H), 4.05–3.96 (m, 2H), 3.96–3.91 (m, 1H), 3.64
(s, 3H), 3.61 (dd, J=4.2, 11.2 Hz, 1H), 2.52–2.45 (m, 4H), 2.40 (t,
J=6.8 Hz, 2H), 2.09–2.04 (m, 1H), 1.91–1.78 (m, 4H), 1.33–1.24 (m,
4H), 0.91 (s, 9H); 13C NMR (101MHz, CDCl3) δ: 173.9, 171.0, 170.3 (d,
2J=20.5 Hz), 170.2, 156.8, 150.4, 148.6, 132.4, 131.9, 129.7, 126.4,
121.7, 112.1, 79.5, 70.3, 67.7, 58.6, 57.5, 56.6, 51.7, 38.9, 36.0, 35.5,
33.7, 28.8, 26.4, 21.8, 16.2, 13.8 (d,2 J=3.7 Hz), 13.7 (d, 2J=3.7 Hz).
MS: calculated for C32H44FN4O7S [M+H]+: m/z=647.3; observed:
m/z=647.7.







Compound 17c (30mg, 0.046mmol, 1 eq.) was dissolved in a
mixture of THF (2mL) and water (0.50mL). Then LiOH was added
(2.2 mg, 0.0928mmol, 2 eq.) and the mixture was stirred at r.t. for 2 h.
LC-MS analysis (acidic method) showed complete conversion of the
starting material. A solution of HCl 4 N in dioxane was added to
pH < 6 and the mixture was evaporated to dryness to yield the de-
protected carboxylic acid derivative (25mg, yield: quantitative).
Starting from the crude carboxylic acid (0.023mmol, 1 eq.) and fol-
lowing the general method H, the desired compound was obtained
(5mg, yield: 22%). 1H NMR (500MHz, CDCl3) δ: 8.66 (s, 1H), 7.47 (t,
J=7.9 Hz, 1H), 7.29 (dd, J=2.2, 7.7 Hz, 1H), 7.07 (d, J=7.2 Hz,
1H), 6.97 (dd, J=3.1, 8.6 Hz, 1H), 6.95–6.94 (m, 1H), 6.85–6.83 (m,
1H), 4.90–4.80 (m, 1H), 4.68 (ddd, J=7.7, 7.7, 1.9 Hz, 1H), 4.55–4.45
(m, 3H), 4.38–4.30 (m, 1H), 4.05–3.93 (m, 3H), 3.60 (qd, J=1.9,
11.2 Hz, 1H), 3.47–3.36 (m, 4H), 2.85–2.60 (m, 3H), 2.50 (s, 3H),
2.47–2.40 (m, 1H), 2.34–2.25 (m, 2H), 2.11–2.02 (m, 2H), 1.90–1.81
(m, 4H), 1.36–1.17 (m, 4H), 0.90 (d, J=3.1 Hz, 9H); 13C NMR
(126MHz, CDCl3) δ: 173.9, 171.4, 171.2, 170.5, 170.4, 170.3, 169.7,
169.6, 169.0, 168.9, 167.6, 156.9, 150.4, 148.7, 147.0, 136.4, 132.7,
131.8, 130.2, 130.1, 126.2, 121.8, 121.8, 117.0, 112.3, 112.1, 79.4,
70.3, 67.9, 58.8, 57.7, 56.8, 56.7, 49.2, 49.1, 42.3, 39.3, 39.2, 39.1,
36.4, 36.1, 35.5, 31.6, 28.8, 28.7, 26.5, 22.9, 16.3, 13.9 (d,
2J=3.7 Hz), 13.8 (d, 2J=3.7 Hz). HRMS analysis: calculated for





To a solution of compound 19 (0.042mmol), HATU (16mg,
0.042mmol), HOAT (5.71mg, 0.042mmol) 1-fluorocyclopropane-1-
carboxylic acid (4.3mg, 0.042mmol) in DMF (1mL), DIPEA (25 µL,
0.141mmol) was added. The reaction mixture was stirred at r.t. for
30min. LC-MS analysis (acidic method) showed complete conversion of
the starting material. Water (1mL) was added and the resulting mixture
was extracted with DCM (3×5mL). After drying the organic phase
over MgSO4 and the solvent was removed under reduced pressure to
afford the title compound (28.3mg, 85% yield) which was used without
further purification.1H NMR (400MHz, CDCl3) δ 8.71 (s, 1H),
7.54–7.51 (m, 6H), 7.34–7.31 (m, 3H), 7.25–7.19 (m, 12H), 4.69–4.64
(m, 1H), 4.38–4.36 (m, 1H), 4.32–4.19 (m, 2H), 3.66 (d, J=4.2 Hz,
1H), 3.50 (d, J=11.6 Hz, 1H), 3.26 (dd, J=3.9, 11.6 Hz, 1H), 3.09 (d,
J=5.9 Hz, 1H), 2.41–2.33 (m, 1H), 2.14–2.07 (m, 1H), 1.38–1.21 (m,
7H), 0.97 (s, 3H). 19F NMR: −197.41. MS analysis: calculated for
C44H45FN4O4S2: 776.3; observed: 777.3 [M+H]+.
The trityl protected compound (0.04mmol) was dissolved in 1.8 mL
of DCM. TIPS (0.1 mL) and TFA (0.1 mL) were added, and the mixture
was left to react at r.t. for 2 h. LC-MS analysis (acidic method) showed
complete conversion of the starting material. Volatiles were removed
and the crude was dissolved in MeOH, filtered and purified by pre-
parative HPLC and freeze-dried to give pure deprotected compound as
white solid (16mg, 79% yield). 1H NMR (500MHz, CDCl3) δ: 8.72 (s,
1H), 7.44 (br.s, 1H), 7.39 (d, J=9.4 Hz, 2H), 7.36 (d, J=7.8 Hz, 2H),
7.15 (br. s, 1H), 4.71 (t, J=7.9 Hz, 1H), 4.64 (d, J=8.5 Hz, 1H),
4.60–4.55 (m, 2H), 4.36 (dd, J=5.3, 14.8 Hz, 1H), 4.15–4.12 (m, 1H),
3.74 (dd, J=3.5, 11.3 Hz, 1H), 2.70 (s, 1H), 2.60 (s, 1H), 2.53–2.46
(m, 4H), 2.20–2.13 (m, 1H), 1.39–1.30 (m, 10H). 19F NMR: −197. 80.
13C NMR (101mHz, CDCl3): 169.7 (d, 2J=20.7 Hz), 169.4, 169.2,
169.5, 147.3, 137.0, 130.0, 128.7, 127.2, 77.05 (d, 1J=232.0 Hz),
69.1, 57.9, 56.6, 55.5, 45.0, 42.3, 35.3, 29.5, 27.7, 14.9, 13.0 (d,
2J=10.6 Hz), 12.8 (d, 2J=10.5 Hz). MS: calculated for




Starting from compound 20 (20mg, 0.037mmol, 1 eq.), 16a
(15mg, 0.041mmol, 1.1 eq.) and DBU (6,3 µL, 0.041, 1.1 eq.), and
following the general method G, compound 21a was obtained (15mg,
yield: 46%). 1H NMR (400MHz, CDCl3) δ: 8.64 (s, 1H), 7.33 (dd,
J=8.1, 14.2 Hz, 4H), 4.78 (d, J=8.3 Hz, 1H), 4.74 (t, J=7.6 Hz, 1H),
4.53–4.49 (m, 1H), 4.42 (ddt, J=6.0, 13.9, 13.2 Hz, 2H), 3.96 (s, 2H),
3.96–3.91 (m, 1H), 3.81 (dd, J=4.2, 11.1 Hz, 1H), 3.68–3.43 (m,
10H), 2.79–2.64 (m, 2H), 2.49 (s, 3H), 2.44–2.36 (m, 1H), 2.23–2.15
(m, 1H), 1.44 (s, 9H), 1.35–1.24 (m, 10H); 13C NMR (101MHz, CDCl3)
δ: 170.8, 170.2 (d, 2J=20.7 Hz), 169.8, 169.6, 150.2, 148.5, 138.1,
131.6, 131.0, 129.5, 128.3, 128.2, 81.7, 79.3, 77.3, 77.0, 76.7, 70.7,
70.5, 70.5, 70.4, 70.2, 69.9, 69.0, 59.1, 56.4, 56.0, 47.9, 43.0, 36.8,
28.4, 28.1, 25.8, 25.1, 16.1, 13.9 (d, 2J=4.8 Hz),13.8 (d, 2J=4.8 Hz).







Starting from compound 21a (15mg, 0.019mmol) and following
the general method B the deprotected carboxylic acid derivative was
obtained in quantitative yield (13.9mg). Starting from the crude car-
boxylic acid (0.019, 1 eq.) and following the general method H, the
desired compound was obtained (11mg, yield: 56%). 1H NMR
(400MHz, MeOD) δ: 8.86 (s, 1H), 7.55 (dd, J=7.2, 8.5 Hz, 1H),
7.46–7.40 (m, 4H), 7.13 (d, J=9.0 Hz, 1H), 7.05 (d, J=7.5 Hz, 1H),
5.04 (dd, J=5.6, 12.8 Hz, 1H), 4.93 (s, 1H), 4.60 (t, J=8.4 Hz, 1H),
4.54–4.35 (m, 3H), 3.95 (s, 2H), 3.88 (d, J=3.1 Hz, 2H), 3.59–3.45
(m, 14H), 2.89–2.65 (m, 5H), 2.47 (s, 3H), 2.28–2.23 (m, 1H),
2.14–2.06 (m, 2H), 1.42–1.25 (m, 10H); 13C NMR (101MHz, MeOD) δ:
174.6, 174.0, 173.5, 171.6, 171.5 (d, 2J=21.2 Hz) 171.4, 170.8,
170.6, 169.3, 152.8, 149.1, 148.2, 140.2, 137.3, 134.0, 133.4, 131.6,
130.4, 129.0, 118.1, 112.2, 111.6, 79.1 (d, 1J=231.9 Hz), 72.0, 71.7,
71.4, 71.3, 71.1, 71.0, 61.1, 58.1, 57.2, 50.2, 43.7, 42.5, 39.5, 39.0,
32.2, 29.6, 27.0, 25.7, 23.8, 15.9, 14.2, 14.1 (t, 2J=9.5 Hz). HRMS






Starting from compound 20 (20mg, 0.037mmol, 1 eq.), 16b
(19mg, 0.041mmol, 1.1 eq.) and DBU (6,3 µL, 0.041, 1.1 eq.), and
following the general method G, the titled compound was obtained
(19.4 mg, yield: 66%). 1H NMR (400MHz, CDCl3) δ: 8.65 (s, 1H), 7.34
(dd, J=8.3, 13.6 Hz, 4H), 4.81 (d, J=8.5 Hz, 1H), 4.74 (t, J=7.7 Hz,
1H), 4.53–4.50 (m, 1H), 4.42 (ddt, J=5.8, 15.2, 15.3 Hz, 2H), 3.98 (s,
2H), 3.94–3.80 (m, 2H), 3.70–3.42 (m, 18H), 2.80–2.64 (m, 2H), 2.49
(s, 3H), 2.43–2.36 (m, 1H), 2.24–2.15 (m, 1H), 1.44 (s, 9H), 1.33–1.24
(m, 10H); 13C NMR (101MHz, CDCl3) δ: 171.0, 170.3 (d, 2J=20.5 Hz),
169.9, 169.8, 150.4, 148.6, 138.3, 131.7, 131.1, 129.6, 128.3, 81.7,
79.4, 70.9, 70.7, 70.6, 70.3, 70.0, 69.2, 59.3, 56.5, 56.0, 48.1, 43.2,
37.0, 28.6, 28.3, 25.9, 25.2, 16.2, 14.0 (d, 2J=2.9 Hz), 13.9 (d,
2J=2.9 Hz). MS: calculated for C41H62FN4O11S2 [M+H]+: m/
z=869.4; observed: m/z=869.3.







Starting from compound 21b (19.4mg, 0.022mmol) and following
the general method B the deprotected carboxylic acid derivative was
obtained in quantitative yield (17mg, yield: quantitative). Starting
from the crude carboxylic acid (0.011mmol, 1 eq.) and following the
general method H, the desired compound was obtained (7.3 mg, yield:
47%). 1H NMR (500MHz, MeOD) δ: 8.86 (s, 1H), 7.55 (dd, J=7.2,
8.6 Hz, 1H), 7.44 (dd, J=8.5, 11.4 Hz, 4H), 7.14 (d, J=8.6 Hz, 1H),
7.05 (d, J=7.0 Hz, 1H), 5.04 (dd, J=5.4, 12.4 Hz, 1H), 4.94 (s, 1H),
4.61 (t, J=8.4 Hz, 1H), 4.52–4.37 (m, 3H), 3.96 (s, 2H), 3.92–3.86 (m,
2H), 3.57–3.47 (m, 22H), 2.88–2.66 (m, 5H), 2.48 (s, 3H), 2.28–2.24
(m, 1H), 2.14–2.07 (m, 2H), 1.42–1.27 (m, 10H); 13C NMR (126MHz,
MeOD) δ: 174.7,174.1, 173.6, 171.5 (d, 2J=19.8 Hz) 171.5, 170.8,
170.6, 169.2, 152.9, 149.1, 148.1, 140.2, 137.3, 134.0, 133.4, 131.6,
130.5, 130.4, 129.6, 129.0, 118.1, 112.1, 111.5, 79.1 (d,
1J=231.2 Hz), 72.0, 71.6, 71.6, 71.5, 71.4, 71.3, 71.1, 71.0, 61.1,
58.1, 57.1, 43.6, 42.5, 39.4, 39.1, 32.2, 29.6, 26.9, 25.7, 23.8, 15.9,
14.2 (d, 2J=7.9 Hz), 14.1 (d, 2J=7.9 Hz). HRMS: calculated for





Starting from compound 20 (20mg, 0.037mmol, 1 eq.), methyl 5-
bromobutanoate 16c (8 mg, 0.041mmol, 1.1 eq.) and DBU (6,3 µL,
0.041, 1.1 eq.), and following the general method G, compound 21c
was obtained (16.5mg, yield: 67%). 1H NMR (400MHz, CDCl3) δ: 8.65
(s, 1H), 7.33 (dd, J=8.0, 16.3 Hz, 4H), 4.76–4.71 (m, 2H), 4.50 (t,
J=6.9 Hz, 1H), 4.42 (d, J=6.1 Hz, 2H), 3.97 (d, J=11.8 Hz, 1H),
3.74–3.69 (m, 1H), 3.62 (s, 3H), 2.54–2.37 (m, 6H), 2.24 (t, J=7.6 Hz,
2H), 2.21–2.16 (m, 1H), 1.67–1.58 (m, 2H), 1.52–1.42 (m, 2H),
1.32–1.24 (m, 10H); 13C NMR δ: (101MHz, CDCl3) δ 173.8, 170.9,
170.5 (d, 2J=20.7 Hz), 170.0, 150.5, 148.6, 138.2, 131.7, 131.1,
129.6, 128.2, 79.4, 70.2, 59.2, 56.7, 56.2, 51.7, 48.1, 43.2, 36.9, 33.6,
28.9, 28.0, 25.8, 25.4, 24.4, 16.1, 14.0 (d, 2J=3.4 Hz), 13.9 (d,






Compound 21c (16.5 mg, 0.025mmol, 1 eq.) was dissolved in a
mixture of THF (1mL) and water (0.25mL). Then LiOH was added
(1.2 mg, 0.0509mmol, 2 eq.) and the mixture was stirred at r.t. for 2 h.
LC-MS analysis (acidic method) showed complete conversion of the
starting material. A solution of HCl 4 N in dioxane was added to
pH < 6 and the mixture was evaporated to dryness to yield the de-
protected carboxylic acid derivative (16.1mg, yield: quantitative).
Starting from the crude carboxylic acid (0.025mmol, 1 eq.) and fol-
lowing the general method H, the desired compound was obtained
(9.2 mg, yield: 39%). 1H NMR (500MHz, MeOD) δ: 8.92 (s, 1H), 7.54
(dd, J=7.2, 8.5 Hz, 1H), 7.46–7.39 (m, 4H), 7.07 (dd, J=7.8,
23.5 Hz, 2H), 5.04 (dd, J=5.6, 12.9 Hz, 1H), 4.91 (d, J=9.2 Hz, 1H),
4.61 (t, J=8.3 Hz, 1H), 4.53–4.36 (m, 3H), 3.90–3.82 (m, 2H),
3.48–3.37 (m, 4H), 2.89–2.68 (m, 3H), 2.56 (t, J=7.4 Hz, 2H), 2.48 (s,
3H), 2.29–2.22 (m, 1H), 2.14–2.08 (m, 4H), 1.67–1.55 (m, 2H),
1.51–1.43 (m, 2H), 1.41–1.25 (m, 10H); 13C NMR (126MHz, MeOD) δ:
176.4, 174.6, 174.1, 171.5, 170.9, 170.6, 169.3, 153.0, 148.7, 148.2,
140.3, 137.2, 134.0, 133.6, 131.4, 130.5, 130.4, 129.5, 129.0, 118.0,
112.1, 111.5, 79.1 (d, 1J=232.0 Hz) 71.0, 61.1, 58.1, 57.3, 57.2, 43.7,
42.8, 39.8, 39.0, 36.4, 32.2, 30.2, 29.0, 27.1, 26.2, 25.7, 23.8, 15.7,
14.2, 14.1 (dd, 2J=9.1 Hz). HRMS: calculated for C45H53FN8O9S2
[M+H]+: m/z=933.3434; observed: m/z=933.3263.
4.2. Biology
4.2.1. Cell culture
HeLa (CCL-2) and HEK293 (CRL-1573) cells were purchased from
ATCC and cultured in DMEM medium (Gibco) supplemented with 10%
FBS, 100 µg/mL penicillin/streptomycin and L-glutamine. Cells were
grown at 37 °C and 5% CO2, and were propagated no longer than 30
passages. All cell lines were routinely tested for mycoplasma con-
tamination using MycoAlert kit from Lonza.
4.2.2. Evaluation of cellular activity of PROTACs
HeLa (5×105) and HEK293 (1× 106) cells were seeded in stan-
dard 6-well plates (2mL medium) overnight before treatment with
compounds at the desired concentration and a final DMSO concentra-
tion of 0.1% v/v. After the appropriate incubation time, cells were
washed with DPBS (Gibco) and lysed using 85 µL RIPA buffer (Sigma-
Aldrich) supplemented with cOmplete Mini EDTA-free protease in-
hibitor cocktail (Roche) and benzonase. Lysates were clarified by cen-
trifugation (20000 g, 10 min, 4 °C) and the total protein content of the
supernatant was quantified using a Bradford colorimetric assay.
Samples were prepared using LDS sample buffer (Invitrogen) and equal
amounts of total protein.
4.2.3. Immunoblotting
Proteins were separated by SDS-PAGE on NuPage 4–12% Bis-Tris
gels and transferred to Amersham Protran 0.45 NC nitrocellulose
membranes (GE Healthcare) using wet transfer. Membranes were
blocked using 5% w/v milk in Tris-buffered saline (TBS) with 0.1%
Tween-20. Blots were probed using anti-VHL (CST-68547), anti-CRBN
(Novus, NBP1-91810) and anti-β-tubulin hFAB-rhodamine (BioRad,
12004166) primary antibodies, followed by incubation with secondary
anti-Rabbit IRDye 800CW (ab216773) or anti-rabbit HRP-conjugated
(CST-7074) antibodies. Blots were developed using a Bio-Rad
ChemiDoc MP Imaging System or the Amersham ECL Prime western
blotting detection kit and Amersham Hyperfilm ECL film, as appro-
priate. Band quantification was performed using the ImageJ software.
Band intensities were normalized to the β-tubulin loading control and
reported as % of the average 0.1% DMSO vehicle intensity. Degradation
data was plotted and analysed using Prism (Graphpad, version 7). DC50
values (concentration to reach 50% maximal degradation) were esti-
mated by fitting band intensity against log[concentration]. Apparent
half-life values (time to reach 50% maximal degradation) were esti-
mated by fitting band intensity against time using a single-phase ex-
ponential decay model.
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Notes
While this manuscript was in advanced stage of preparation, related
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hetero-bifunctional VHL-CRBN PROTACs were published by C.
Steinebach et al. Chem. Commun., DOI: 10.1039/C8CC09541H as an
Accepted Manuscript, in which preferential degradation of CRBN over
VHL was also observed with a compound different from 14a.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bmc.2019.02.048.
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